Invasight Founders Sam Fulcher And Karthiga Kumar

Invasight

Invasight is a Swiss-based early-clinical stage biotech start-up. Our breakthrough technology, ACINDA accelerates drug discovery and enables design of specific protein-protein interaction antagonists (PPIAs) for non-traditional intercellular protein targets, which cause cancer cell invasion. Our first-in-class PPIAs combine potent anti-tumour activity with a favourable safety profile for patients with invasive cancers. The most advanced of these first-in-class, protein-protein interaction antagonists is F2i, a inhibitor of pro-invasive FGFR signalling. F2i is currently in 'pre-clinical' validation stage of drug development.

Press releases

Press
7. June 2022

Invasight closes CHF 4.5 million oversubscribed seed round

The funds will accelerate the development of targeted therapies with superior safety profile for patients with invasive cancers. Zurich, Switzerland, 7 June 2022 – Invasight AG, a Swiss pre-clinical stage biotech company with a mission to develop their breakthrough targeted therapies for invasive cancers, announced the closing of a CHF 4.5 million seed round. The seed financing round was led by OCCIDENT and co-led by JFG Life Sciences Foundation, with participation from Verve Ventures,
 

Info & Contact

Sam Fulcher, Co-founder
Web:
invasight.com

Address

Lengghalde 5
8008 Zürich
Schweiz

In portfolio

HTGF Manager

 
Dr. Julian Zachmann, Investment Manager